PGS Publication: PGP000125

Publication Information (EuropePMC)
Title Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease.
PubMed ID 33185476(Europe PMC)
doi 10.1161/circulationaha.120.051927
Publication Date Nov. 13, 2020
Journal Circulation
Author(s) Marston NA, Patel PN, Kamanu FK, Nordio F, Melloni GM, Roselli C, Gurmu Y, Weng LC, Bonaca MP, Giugliano RP, Scirica BM, O'Donoghue ML, Cannon CP, Anderson CD, Bhatt DL, Steg PG, Cohen M, Storey RF, Sever P, Keech AC, Raz I, Mosenzon O, Antman EM, Braunwald E, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CT.
Released in PGS Catalog: Jan. 7, 2021

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported

PGS Developed By This Publication

Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution PGS Scoring File (FTP Link)
PGS000665
(GRS_32)
PGP000125 |
Marston NA et al. Circulation (2020)
Ischemic stroke Ischemic stroke,
stroke
32
-
http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000665/ScoringFiles/PGS000665.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM001373 PGS000665
(GRS_32)
PSS000602|
European Ancestry|
51,288 individuals
PGP000125 |
Marston NA et al. Circulation (2020)
Reported Trait: Incident ischemic stroke Hazard Ratio (HR, top vs. bottom tertile): 1.24 [1.05, 1.45]
Hazard Ratio (HR, intermediate vs. bottom tertile): 1.15 [0.98, 1.36]
age, sex, PCs(1-5), hypertension, hyperlipidemia, diabetes mellitus, smoking, bascular disease, congestive heart failure, atrial fibrillation
PPM001374 PGS000665
(GRS_32)
PSS000602|
European Ancestry|
51,288 individuals
PGP000125 |
Marston NA et al. Circulation (2020)
Reported Trait: Incident ischemic stroke C-index: 0.65 [0.63, 0.66] Clinical variables from the Revised Framingham Stroke Risk score, geographic region
PPM001375 PGS000665
(GRS_32)
PSS000601|
European Ancestry|
11,187 individuals
PGP000125 |
Marston NA et al. Circulation (2020)
Reported Trait: Incident ischemic stroke in individuals with atrial fibrillation Hazard Ratio (HR, top vs. bottom tertile): 1.29 [1.01, 1.64] age, sex, PCs(1-5), hypertension, hyperlipidemia, diabetes mellitus, smoking, bascular disease, congestive heart failure, atrial fibrillation, components of CHA2DS2-VASc score

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000602 The endpoint of interest was ischemic stroke. In each trial, ischemic stroke was formally adjudicated by an independent clinical endpoint committee blinded to treatment assignment. Median = 2.5 years
[
  • 960 cases
  • , 50,328 controls
]
,
71.7 % Male samples
Mean = 65.9 years
Sd = 9.2 years
European ENGAGE AF-TIMI 48, FOURIER, PEGASUS-TIMI 54, SAVOR-TIMI 53, SOLID-TIMI 52
PSS000601 All patients with atrial fibrillation and CHADS2 score of 2 or higher who were treated with anticoagulation. The endpoint of interest was ischemic stroke. In each trial, ischemic stroke was formally adjudicated by an independent clinical endpoint committee blinded to treatment assignment. Median = 2.8 years
[
  • 395 cases
  • , 10,792 controls
]
,
60.78 % Male samples
Mean = 70.8 years
Sd = 9.1 years
European ENGAGE AF-TIMI 48